Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 9/20 | 0.45 |
| ▸ | PPARG | P37231 | 8/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12618058 | 0.86 | ALDH1A1 (0.61) | ALDH1A1HPGDTP53L3MBTL1KDM4E | |
| SCHEMBL5759674 | 0.85 | TARBP2 (0.54) | ALDH1A1TP53SMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL5025952 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HPGDTP53NFKB1NFKB2 | |
| SCHEMBL3973849 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HPGDTP53NFKB1NFKB2 | |
| SCHEMBL3530493 | 0.78 | RAB9A (0.53) | ALDH1A1HPGDTP53SMN1; SMN2HSD17B10 | |
| SCHEMBL5762128 | 0.77 | PPARA (0.57) | ALDH1A1TP53SMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL9411857 | 0.77 | MAPT (0.38) | ALDH1A1HPGDTP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL3532628 | 0.77 | KDM1A (0.57) | ALDH1A1HPGDKDM4EPPARAPPARG | |
| SCHEMBL28295550 | 0.75 | PPARA (0.46) | ALDH1A1TP53KDM4EPPARAPPARG | |
| SCHEMBL4885518 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HPGDSMN1; SMN2HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| CN-1713907-B | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| US-7314884-B2 | non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile | HOFFMANN-LA ROCHE INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | disclosed |
| CN-1713907-A | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE (CH) | 2005-12-28 | — | — | CN | disclosed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | ALDH1A1 233/4885HPGD 2181/4885TP53 4661/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | ALDH1A1 133/4885HPGD 2329/4885TP53 4814/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | ALDH1A1 233/4885HPGD 2181/4885TP53 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.